Introduction
Transcription factor c-Myb has been implicated in the regulation of cell proliferation, dierentiation and apoptosis in cells of the hematopoietic system and in the gastrointestinal tract (reviewed byOh and Reddy, 1999; Weston, 1998) . Its over-expression has been shown in various hematopoietic malignancies (Slamon et al., 1984; , implying that deregulation of c-Myb activity is involved in the genesis of cancer. Hematopoiesis is markedly impaired and embryonic colon development is disrupted in c-myb null mice (Mucenski et al., 1991; Zorbas et al., 1999) .
Regulation of c-Myb activity occurs at many levels, including regulation of c-myb expression via a transcriptional attenuation site found within intron 1 (Bender et al., 1987; Thompson et al., 1997; Watson, 1988) and post-transcriptional mechanisms that regulate the stability of c-myb mRNA (Thompson et al., 1986) . The protein is also subject to modi®cations that aect protein-protein interaction (Ness, 1996) and proteosome-mediated degradation (Bies et al., 2000) .
As a transcription factor, c-Myb functions are largely mediated through speci®c DNA binding that seems to be regulated by phosphorylation (Ness, 1996) . The amino terminal serines 11 and 12 of c-Myb are phosphorylated in vivo (Luscher et al., 1990) . These two serines and adjacent residues ( 11 Ser-Ser-Asp-Glu-Asp 15 ) form consensus phosphorylation sites for casein kinase 2 (CK2), and can be phosphorylated by CK2 in vitro (Luscher et al., 1990; Ramsay et al., 1995) . These residues are highly conserved in vertebrate c-Myb proteins, although the exact function of phosphorylation at these sites is unclear. In vitro studies performed by us have shown that constitutive phosphorylation by CK2 at serines 11 and 12 is essential for high anity speci®c DNA binding activity of full-length c-Myb in vitro . CK2 phosphorylation of c-Myb at serines 11 and 12 has been reported to reduce the eciency of c-Myb DNA binding to low anity sites (Luscher et al., 1990) . These dierences may be of functional signi®cance depending upon the target genes and the abundance of c-Myb. Although both of these studies suggest that CK2 phosphorylation of c-Myb may play some regulatory role, it is unclear when c-Myb phosphorylation at serines 11 and 12 occurs during the cell cycle and how this regulates c-Myb DNA binding activity in vivo.
We have examined whether c-Myb expression and DNA binding activity change during the cell cycle. This has been assessed in primary T-cells and transformed T-cells as they move through the cell cycle, importantly in the absence of cell cycle perturbation. We employed an antibody directed against a c-Myb amino ± terminal peptide containing phosphate groups on serines 11 and 12 to monitor the phosphorylation status and found that serines 11 and 12 are constitutively phosphorylated in vivo. Intriguingly the levels of c-Myb protein markedly increased following stimulation of primary T lymphocytes proliferation, not all of the protein was capable of DNA binding. Furthermore, the DNA binding activity of c-Myb increased proportionally with increasing number of T-cells entering the cycle, then when most cells were in cycle, both c-Myb protein expression and DNA binding activity levels remained unchanged. Although transformed and primary T-cells showed these dierences overall in cycling cells amino-terminal phosphorylation of serines 11 and 12 remains constant through the various phases of the cell cycle.
Results
Characterization of serines 11 and 12 phosphorylation state-specific`MybSerP' sera Sera directed against c-Myb phosphorylated on serines 11 and 12 were successfully generated in rabbits. Figure   1a shows a schematic of the location of serines 11 and 12 and CT3 Myb used as a CK2 substrate for phosphorylation. CT3 Myb generated in E. coli served as an ecient substrate for recombinant CK2 as shown in Figure 1b and previously reported . The speci®c immunoreactivity of these sera against c-Myb phosphorylated at serines 11 and 12 (designated MybSerP) was con®rmed by western blot analysis using CT3 Myb protein (Figure 1c) . Anti-cMyb Mab 5.1 detects an epitope at the C-terminus of CT3 Myb (Ramsay et al., 1989) independent of the phosphorylation status of c-Myb. To eliminate the possibility that MybSerP detected other phosphorylation sites within c-Myb HEK293 cells were transfected with pACT expression constructs encoding wild type, glutamic acid substituted serines at positions 11 and 12 and amino-terminally truncated c-Myb designated NT1 (Sakura et al., 1989) . As Figure 1 Characterization of the MybSerP antibody: (a) Schematic diagram of full-length c-Myb and the structure of a truncated c-Myb protein; CT3 Myb is shown including epitopes of the antibodies used in this study. (DBD-DNA binding domain; NRDnegative regulatory domain). Serines 11 and 12 at the amino terminus of both proteins can be phosphorylated by casein kinase 2 (CK2) in vitro . (b) CT3 Myb incubated in the presence (+) or absence (7) of recombinant D. melanogaster CK2a was transferred onto a PVDF membrane. In vitro phosphorylation of CT3 Myb by CK2 in the presence of [ 32 P]-ATP is shown. (c) Subsequently the same ®lter was subjected to Western blot analysis with either the c-Myb serines 11 and 12 phosphorylation state-speci®c antibody (MybSerP) or c-Myb speci®c but phosphorylation state insensitive Mab5.1 antibody. (d) HEK293 cells were transfected with expression constructs encoding wild type (WT), glutamic acid substitution mutant at residues 11 and 12 (11/12Glu) and amino truncated c-Myb protein (NT1). Cell lysates were probed with MybSerP and Mab1.1 antibodies to document the speci®city of the anti-phosphoserines 11 and 12 antibody expected anti-c-Myb Mab 1.1 (Ramsay et al., 1989) detected the three dierent c-Myb proteins including the amino-terminally truncated protein while MybSerP detected only the wild type protein (Figure 1d ).
Analysis of CCRF-CEM cells throughout the cell cycle
A highly homogeneous G 1 population of CEM cells was obtained by centrifugal elutriation. Following reculture in warm complete medium, this G 1 population synchronously progressed through the cell cycle as determined by¯ow cytometry measuring DNA content (Figure 2a) . The G 1 population moved into the S phase by 6 h, then into G 2 /M by approximately 8 h with some cells returning to G 1 by 10 h. Protein extracts from CEM cells synchronized through the cell cycle were subjected to western blot analysis. This revealed that expression levels of c-Myb, amino ± terminal phosphorylated c-Myb and the alpha subunit of CK2 do not change as cells progress from G 1 to S and G 2 /M phase of the cell cycle (Figure 2b ). These data suggest that the relative level of CK2 phosphorylated c-Myb did not change during progression through the cell cycle. Additionally, the DNA binding activity of c-Myb determined by EMSA using the MBS-1 probe and the same protein extracts from synchronized CEM cells, does not change with cell cycle progression (Figure 3a) .
To examine whether CK2 activity changed during the cell cycle even though the abundance of the catalytic unit CK2a did not change we performed kinase assays using a CK2 speci®c substrate. In addition we tested CDK2 activity at each time point as this kinase activity should increase as cells move out of the G 1 phase (Pines, 1994) . Kinase assays using synthetic peptide substrates revealed that while the speci®c activity of CDK2 increases over 3.5-fold, as CEM cells progress from the G 1 towards the G 2 /M phase of the cell cycle, the speci®c activity of CK2 does not change (Figure 3b ). 
Analysis of quiescent T-cells recruited into the cell cycle
Normal human T lymphocytes isolated using a Ficoll ± Paque density gradient were stimulated to proliferate using PHA. Flow cytometry analysis of PI stained T lymphocytes shows that a fraction of quiescent cells stimulated with PHA are induced to enter the cell cycle, from G 0 /G 1 within the ®rst 18 h, then into S phase within 18 ± 24 h and G 2 /M after 24 h ( Figure  4a ). However, the entry of quiescent T lymphocytes into the cell cycle following PHA stimulation did not occur in a synchronous manner. The levels of c-Myb, serines 11 and 12 phosphorylated c-Myb and CK2a protein expression associated with cell cycle entry and cell cycle progression of T lymphocytes was analysed using western blotting of the same extracts. This showed that c-Myb is transiently expressed at high levels in the early phase of the cell cycle, with a peak of c-Myb expression at 19 h after PHA stimulation ( Figure 4b ). Densitometric analysis of Western blots shows that c-Myb expression increases 3 ± 4 fold from 0 ± 19 h. Subsequently, c-Myb levels decreased to a basal level slightly higher from that observed in quiescent cells. Phosphorylation at serines 11 and 12 of endogenous c-Myb paralleled that observed for total c-Myb (Figure 4b ). Furthermore, the protein expression levels of CK2a underwent a steady but marked increase (approximately 4 ± 5 fold as determined by densitometric analysis) from 0 ± 72 h after PHA stimulation of T lymphocytes (Figure 4b ).
When the DNA binding activity of c-Myb was investigated by EMSA with the same extracts from quiescent and PHA stimulated T lymphocytes, it was found to steadily increase as quiescent T lymphocytes are stimulated to proliferate. The increase in c-Myb DNA binding activity reached 2 ± 3 fold after 66 h of PHA stimulation (Figure 5a ). It appears that c-Myb DNA binding activity does not correlate to the levels of c-Myb protein in T lymphocytes following PHA stimulation. This is most evident at the 19 h time point, where the levels of c-Myb protein are highest but are not accompanied by a rise in the DNA binding activity. CDK2 and CK2 enzyme activity was also examined in human T lymphocytes. Although CDK2 and CDK2 speci®c kinase activities were determined using synthetic peptide substrates and plotted relative to the 0 h activity enzyme activity increased by approximately 15-fold as cells progress into the cell cycle from a quiescent state, there is no change in CK2 enzyme activity (Figure 5b ) despite an apparent increase in CK2a protein levels. In contrast, the progressive increase in CDK2 activity observed as cells progress through the cell cycle in both CEM cells and PHA stimulated T lymphocytes is consistent with cell cycle progression documented by FACS analysis.
Transactivation of c-myb dependent reporters by c-Myb serines 11/12 mutant proteins Although we found no evidence for phosphorylation changes in the amino ± terminus of c-Myb or DNA binding activity during cell cycle progression, the issue of the transactivating capacity of c-Myb was not addressed. Therefore to assess eects of serines 11 and 12 phosphorylation we examined CV-1 cells that were transfected with expression vectors encoding wild type full length c-Myb and mutant proteins with either alanine or glutamic acid substitutions of serines 11 and 12. Their capacity to activate a reporter construct with tandem repeats of the c-Myb binding site, MBS-1 was measured. Figure 6 shows no dierence in transient protein expression of the c-Mybs or CAT reporter activity. These data suggest that c-Myb activity is not dependent upon the phosphorylation status of residues 11 and 12 in the amino terminus of c-Myb.
Discussion
Regulation of c-Myb activity occurs at many levels. The focus of this study was to examine regulation by phosphorylation of serine residues 11 and 12. Although in vitro studies suggest that phosphorylation at serines 11 and 12 by CK2 mediates DNA binding activity (Luscher et al., 1990; Ramsay et al., 1995) , it was unclear whether and when CK2 phosphorylation regulates c-Myb in vivo.
To determine the degree of phosphorylation at serines 11 and 12 of c-Myb in the context of cell cycle entry and cell cycle progression, the T leukemia cell line CCRF-CEM and normal human T lymphocytes were used for analysis. Cycling CEM cells were subjected to centrifugal elutriation to isolate a highly enriched G 1 sub-population. This technique is ideal and desirable principally because synchronization can be achieved without metabolic intervention or drug assisted cell cycle arrest. In addition, CEM cells employed under these conditions moved through the cell cycle as a population without apparent delay. In contrast, the analysis of events associated with the initial stages of cell proliferation, principally entry into the cell cycle denoted by the G 0 /G 1 transition, was performed on peripheral T lymphocytes followed by mitogenic stimulation.
Analysis of protein levels in CEM cells isolated at dierent phases of the cell cycle revealed that c-Myb protein expression is constitutive and shows no change in its phosphorylation status at serines 11 and 12 during the cell cycle. Although, these studies do not speci®cally address the stoichiometry of serines 11 and 12 phosphorylation our studies suggest that most, if not all of the c-Myb in the cell is phosphorylated at these residues. Furthermore, there were no¯uctuations in speci®c DNA binding activity. This would be expected if phosphorylation of serines 11 and 12 is required for ecient high anity DNA binding . Similarly, there were nō uctuations in activity or expression of the catalytic alpha subunit of CK2 at dierent phases of the cell cycle. Other studies (not shown) using cell cycle perturbations such as addition of a-Polymerase inhibitor, aphidicolin or g-irradiation did not aect any of the above parameters even though the cells were either transiently or persistently blocked in S or G 2 -phase. As others have shown that the c-Myb protein in CEM has a half-life of approximately 1 h (Lipsick and Boyle, 1987) any marked eect on new c-Myb synthesis would have been revealed. Furthermore the stable expression of an activated dominant negative c-Myb did not aect cell cycle progression but did increase the level of spontaneous apoptosis (data not shown). Figure 6 A mixture of CAT reporter DNA, in which the six tandem repeats of Myb-binding site were linked to the CAT gene, the plasmid DNA encoding wild-type c-Myb (WT), the mutants where the Ser-11, 12 were mutated into alanine (Ala) or glutamic acid (Glu), or empty vector, and the internal control plasmid pRSV-b-gal were transfected into CV-1 cells. CAT assays were performed, and the degree of trans-activation (compared to samples empty vector) was measured. Data represents average of three experiments with standard deviations. At the same time, the levels of c-Myb expression were examined by Western blotting and indicated above each lane
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Taken together, these observations suggest that the cMyb protein is continuously synthesized and its abundance and activity are not regulated as a consequence of passage through the cell cycle. Similarly it does not appear that c-Myb is required for cell cycle progression at least when T-cells are in cycle. In contrast, quiescent T lymphocytes stimulated to re-enter the cell cycle show dierent patterns of protein expression and activity. Freshly isolated T lymphocytes, which are characteristically in G 0 (Darzynkiewicz et al., 1976) , seem to have relatively low levels of cMyb. Although these levels markedly increased following mitogenic stimulation, they were not maintained at an elevated level for the entire stimulation period. The change in c-Myb protein levels correlate with the changes in c-myb mRNA levels observed in quiescent and stimulated T lymphocytes (Golay et al., 1991; Thompson et al., 1986) . Interestingly, the level of DNA binding activity and protein abundance in the same extracts was transiently uncoupled in primary T-cells at 19 h post PHA stimulation. This observation suggests that negative regulation of c-Myb may occur in primary cells when the abundance of c-Myb is uncharacteristically high. These data are in accord with observations from DNA binding, transactivation and transformation studies employing c-Myb proteins with leucine zipper mutations that suggest homodimerization may sequester over-expressed c-Myb proteins into inactive complexes (Nomura et al., 1993; Ramsay et al., 1995) .
The general observation that the levels of c-Myb found in a phosphorylated state at serines 11 and 12 correlate with the total level of c-Myb suggests that endogenous c-Myb is found mostly in a phosphorylated state at serines 11 and 12 and does not change in actively cycling cells. Although the protein levels of the catalytic subunit of CK2a progressively increased several fold following mitogenic stimulation of T lymphocytes, a corresponding increase in kinase activity was not observed. These observations suggest that CK2 activity is also constitutive and not subject to further increases in activity simply through the increase in the catalytic unit production alone.
The transiently elevated levels of c-myb mRNA previously reported in T lymphocytes following mitogenic stimulation have been ascribed an importance based mostly upon the inhibitory eect of antisense oligonucleotides directed against c-myb (Gewirtz et al., 1989; Venturelli et al., 1990) . However, these data and ours equally support the view that low to moderate levels of c-Myb activity are required for complete emergence from quiescence as none of these experiments discriminated between partial or total inhibition of c-Myb function. More recent evidence for the role of c-Myb beyond cell cycle has been reported following the investigation of c-myb 7/7 T-cells and in transgenic mice expressing the dominant negative Myb (Allen et al., 1999; Badiani et al., 1994) . Both of these studies suggest that c-Myb is required for maturation and dierentiation of various T-cell subsets but not speci®cally their proliferation. Alternatively, as the levels of c-Myb DNA binding activity progressively increased following PHA stimulation there is concordance between the levels of c-Myb DNA binding activity and the number of cells being recruited into cycle. However, it is notable that only a fraction of the lymphocyte population is moving into cycle at any one time. This suggests additional priming events are required beyond activation of c-Myb before a cell enters cycle. Finally, population studies often used to assess proliferation are subject to the compounding eects of parallel apoptosis (Sala et al., 1996; Taylor et al., 1996) .
In summary, we have shown that c-Myb DNA binding activity in quiescent (non-cycling) T cells is relatively low comparing to that of cycling cells. Although c-Myb protein levels increase rapidly this does not lead to a commensurate increase in DNA binding activity. Similarly, there was no suggestion of this activity being regulated in primary or transformed human T cells by CK2 phosphorylation at position residues 11 and 12 of c-Myb.
Materials and methods

Cells
Human acute lymphoblastic T-cell leukemia cell line CCRF-CEM McCarthy et al., 1965; Norman and Thompson, 1977) were grown as a suspension culture at 378C, 5% CO 2 , in RPMI-1640 with 20 mM HEPES medium supplemented with 10% fetal bovine serum (FBS) (MultiSer, Trace Biosciences). The antibiotic gentamicin (David Bull Laboratories) was added to the medium at a ®nal concentration of 20 mg/ml. CV-1 cell propagation is described elsewhere .
Transactivation assays
A mixture of 6 mg of pA10CAT6MBS-I CAT reporter DNA, in which the six tandem repeats of Myb-binding site MBS-I and the SV40 early promoter were linked to the CAT gene, 6 mg of the plasmid DNA encoding wild-type or mutant cMyb, or no protein, and 1 mg of the internal control plasmid pRSV-b-gal were transfected into CV-1 cells using the CaPO4 method. Forty hours after transfection, CAT assays were performed as previously described . A sample of cells were lysed in buer (50 mM Hepes, pH 7.5, 250 mM NaCl, 0.2 mM EDTA, 10 mM NaF, 0.5% Nonidet P-40), and cell lysates, normalized to comparable b-galactosidase activity, were used for Western blotting with the anti-cMyb monoclonal antibody 1.1 and ECL detection reagents (Amersham Pharmacia Biotech).
Centrifugal elutriation of CEM cells
The elutriation system was set up as described previously (Kauman et al., 1990) . Approximately 5 ± 10610 7 cells growing exponentially at a density of 1 ± 5610 5 cells/ml were harvested by centrifugation at 1300 r.p.m. then resuspended in 40 ± 50 ml of RPMI-1640/HEPES medium containing 3% FBS. This medium was also used in the elutriation protocol. Elutriation of cells was performed in the Beckman J6 ME centrifugal elutriator with a JE-5 elutriation rotor, at 1500 r.p.m. and 238C. The cells were loaded into the elutriation chamber using a variable speed pump at a rate of 35 ml/min. The¯ow rate was then increased slowly to 60 ml/ min. The initial 50 ml fraction was discarded as it typically contained dead cells and debris. The 60 ml/min fraction was collected to a volume of 2 L, pooled and recultured in prewarmed RPMI-1640 with HEPES medium supplemented with 10% FBS for up to 12 h. To analyse cell cycle distribution, approximately 1610 6 cells from each fraction were used for¯ow cytometric analysis.
Isolation and stimulation of peripheral lymphocytes
Human peripheral blood lymphocytes were isolated from a healthy donor by Ficoll ± Paque density gradient centrifugation following the manufacturer's instructions (Pharmacia Biotech). The cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml of penicillin and 50 mg/ml of streptomycin. Cells were stimulated with 0.2% phytohemagglutinin (PHA) for up to 72 h. To monitor the stimulation process, cells were collected at various intervals and analysed by FACS.
Flow cytometric analysis of DNA content
Cells were harvested and washed in PBS by centrifugation at 1300 r.p.m. for 5 min and 48C. Approximately 1610 6 cells were ®xed in 70% ethanol on ice for 30 min, followed by centrifugation as above. The cell pellet was resuspended in 200 ml PBS and kept at 48C until the analysis. Propidium iodide was added to the cell suspension (®nal concentration of 10 mg/ml) and incubated on ice in the dark for 10 min before the DNA content was determined using the FACScan ow cytometer (FACS) (Becton Dickinson).
Peptide synthesis
Peptides used in kinase reactions and immunization were synthesized by the Merri®eld solid-phase procedure (Hodges and Merri®eld, 1975) , and puri®ed by reversed phase HPLC as described previously (Pearson et al., 1993) . The sequences for peptides used are: cyclin dependent kinase 2 (CDK2) peptide substrate (PTHrP 67-94 ) used to assay CDK2 activity; YLTQETNKVETYKEQPLKTPGKKKKAKP and casein kinase 2 (CK2) peptide substrate, (R3D3) used to assay CK2 enzyme activity; RRRDDDSDDD (Lam et al., 1999) . Also, peptide Myb2-20 (ARRPRHSIYSSDEDDEDIE) was used to immunize rabbits.
Phosphorylation and purification of Myb2-20 peptide
Twenty milligrams of the synthetic peptide Myb2-20 was phosphorylated in vitro, using recombinant casein kinase 2 (12.25 mg) in a reaction volume of 2.5 ml, containing 50 mM MOPS pH 7.0, 10 mM MgCl 2 , 150 mM NaCl, 0.1% Tween 80, 10 mM ATP (Tiganis et al., 1993) . The reaction was continued for a total of 24 h with ion spray mass spectrometric monitoring of phosphorylation throughout. The peptide was then separated from excess ATP by acidi®cation (into 30% acetic acid) and passage through AG1-X8 anion exchange resin (Bio-Rad) to bind the ATP. After dilution of the acetic acid to 5%, the peptide was bound to a Sep-Pak (Waters) C18 reversed phase column to remove other buer components, then eluted with 60% acetonitrile in 0.5% acetic acid. The eluted peptide was then puri®ed on a Macro S (Pharmacia) column (25 ml bed volume) in 0.1% tri¯uor-oacetic acid/20% acetonitrile with a linear gradient from 0 to 0.6 M NaCl over 240 min. The¯ow rate was 3 ml/min. The three eluted peaks were characterized by ion spray mass spectrometry to be di-phosphorylated at serines 11 and 12, mono-phosphorylated and unphosphorylated Myb2-20 peptide. The ®rst peak was desalted on a Sep-Pak and dried in an evacuated centrifuge for coupling to keyhole limpet hemocyanin (Sigma).
Coupling of phosphopeptide Myb2-20 to KLH
To enhance antigenicity, the phosphorylated synthetic peptides are coupled to a carrier protein before immunization. The di-phosphorylated Myb2-20 peptide was dissolved in 0.5 ml of PBS (concentration 3 mM) and the carboxyl groups activated with the addition of sulfo-N-hydroxysuccinimide and EDC (N-ethyl-N-(3-dimethyl-aminopropyl)-carbodiimide hydrochloride), both at 6 mM ®nal concentration. Modi®cation of the peptide was monitored by ion spray mass spectrometry and, after 20 h, the activated peptide was then coupled to the amino groups of 1 mg of keyhole limpet hemocyanin. After 30 h at room temperature, the urea byproduct was centrifuged out and the solution was divided into 12 (1 mg/ml) aliquots for injection into rabbits.
Generation of an anti-SerP-c-Myb antibody
Three rabbits were injected subcutaneously with the peptidecarrier conjugates in Freund's complete adjuvant. Two subsequent booster injections were given after 21 and 42 days. One positive rabbit determined by western analysis was anesthetized and terminally bled 2 weeks after the last booster injection. The sera were screened by Western blotting analysis. Positive serum samples were puri®ed using peptide anity chromatography.
Purification of the anti-Ser
P -c-Myb antibody
CNBr activated Sepharose (Pharmacia Biotech) was washed in water then with 10 ml of 1 mM HCl for 30 min, followed by a wash with 50 ml of 0.1 M NaHCO 3 buer, pH 8.0 containing 0.5 M NaCl. The resin was mixed with 1 ml of a 1 mg/ml di-phosphorylated Myb2-20 peptide in a buer containing 0.1 M NaHCO 3 and 0.5 M NaCl for 3 h at room temperature. The resin was allowed to settle, and the unbound, liquid layer was removed. The resin was washed with 10 ml of buer containing 0.1 M NaHCO 3 and 0.5 M NaCl, twice, then with 0.1 M Tris-HCl, pH 8, overnight at room temperature, then with 0.1 M sodium acetate, pH 4.0 and ®nally with 0.1 M Tris-HCl, pH 8. Rabbit serum was mixed with the resin (2 ml of serum to 0.5 ml of resin in a buer containing 0.1 M Tris-HCl, pH 8 and 0.5 M NaCl) for 2 h at room temperature. The protein was eluted from the column with 0.1 M glycine, pH 3 and collected in 0.1 M TrisHCl, pH 8. The solution was dialyzed against PBS overnight. The antibody solution was stored at 48C.
Characterization of the anti-ser 11and12-P -c-Myb antisera Puri®ed E. coli CT3 Myb was generated as previously described . Puri®ed E. coli CT3 Myb was incubated with 16 casein kinase buer (50 mM MOPS, pH 7.0, 10 mM MgCl 2 , 150 mM NaCl, 0.1% Tween 20), 0.08 mg of recombinant Drosophila casein kinase 2 (a 2 b 2 ) and 10 mM ATP in a total volume of 10 ml, at 308C for 1 h. CT3 Myb protein was also radiolabeled in the presence of 0.25 mM [g 32 P]ATP as previously described . The kinase reaction was subjected to electrophoresis on a 10% SDS ± PAGE gel and then transferred to a PVDF membrane.
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The ®lter was exposed to PhosphorImage screen and processed (Molecular Dynamics) to detect radiolabeling. Subsequently, the ®lter was probed with the anti-ser 11 &12-P -c-Myb (MybSerP) antisera at 1 : 500 dilution or an anti-Myb (Mab 5.1) antibody at 1 : 1000 dilution and detected with an goat anti-rabbit or mouse secondary antibody conjugated with alkaline phosphatase (BioRad) as previously described (Ramsay et al., 1989) .
Extraction of protein from cells
Cells were incubated with NP40 lysis buer (0.64% Nonidet P-40, 5 mM KCl, 2 mM MgCl 2 , 10 mM Tris-HCl, pH 8.0) containing 500 mM NaCl, 1 mM PMSF and 10 U Trasylol (Bayor), on ice for 5 ± 10 min. The lysate was centrifuged at 13 000 r.p.m. in a microcentrifuge for 15 min at 48C. The supernatant was stored at 7808C until assayed.
Western blotting
Protein extracts in SDS ± PAGE sample buer were boiled for 5 min then resolved on 10% SDS ± PAGE. Semi-dry electrophoretic transfer to PVDF membranes (ImmobilonP, Millipore) was carried out for 1 ± 2 h at 15 V in a transfer buer containing 25 mM Tris, 19.2 mM glycine, 0.1% SDS and 20% methanol. The membranes were blocked with 10% skim milk powder in TBS (25 mM Tris-HCl, pH 8.2, 144 mM NaCl) and 0.1% Tween 20, for 30 min at room temperature. The membranes were then probed either with the MybSerP (1 : 500), the anti-c-Myb antibody`Mab 5.1' (1 : 1000) or the anti-CK2a antibody (Tiganis et al., 1993) (1 : 1000), overnight at 48C, followed by washes with 16TBS buer containing 0.1% Tween 20. Incubation with the appropriate secondary antibody goat anti-rabbit-AP (-HRP) or goat anti-mouse-AP (-HRP) diluted at 1 : 3000 was carried out for 30 min at room temperature as previously described (Ramsay, 1995; Ramsay et al., 1995) .
Electrophoretic mobility shift assays (EMSA)
These were performed as previously described (Ramsay, 1995) .
Protein kinase assays
Assays were performed in a volume of 40 ml containing 50 mM MOPS pH 7.0, 10 mM MgCl 2 , 150 mM NaCl (only in the CK2 assay), 0.1% (v/v) Tween 80, 250 mM [g-32 P] ATP (500 c.p.m./pmol), 0.1 ± 1 mg/ml peptide substrate and 3 ± 6 mg of protein extract from each time point throughout the cell cycle. Reactions proceeded for 20 min at 308C, after which an aliquot of 30 ml was spotted onto Whatman P81 cation-exchange paper, and washed in 75 mM phosphoric acid as described previously (Pearson et al., 1993) . Cerenkov counting using the [ 3 H] channel in a scintillation counter quantitated the radioactivity incorporated into the peptide. Minus-substrate backgrounds were subtracted for each timepoint. The relative activity was calculated as pmol/min/mg.
